Proteinuria Clinical Trial
— FINALEOfficial title:
A Multicenter, Prospective, Observational Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With Diabetic Kidney Disease and Proteinuria
Verified date | July 2023 |
Source | Boryung Pharmaceutical Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who are given antihypertensives containing fimasartan, in an actual clinical environment where a variety of patient characteristics are reflected.
Status | Completed |
Enrollment | 360 |
Est. completion date | June 5, 2023 |
Est. primary completion date | June 5, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - Male and female adults aged 19 or older - Those who were diagnosed with type 2 diabetes and have been being given stable doses of hypoglycemic agents for 8 weeks or longer - Those in whom albuminuria was found to meet one of the following criteria two times before the administration of the antihypertensive treatment containing fimasartan (results (baseline values) within 4 weeks before the administration of antihypertensives must be ACR or AER results) - An albumin/creatinine ratio (ACR) of 10 mg/g or higher or - An albumin excretion rate (AER) of 10 mg/day or higher or - A proteinuria/creatinine ratio (PCR) of 70 mg/g or higher or - A urine dipstick result of trace to 1+ or higher - Those who plan to be given antihypertensive treatment containing fimasartan for essential hypertension or are being given the treatment (in this case, those with an administration period of 6 weeks or lower can be enrolled) - Those with records of clinical systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 85 mmHg or higher before the antihypertensive treatment containing fimasartan or at the time of the treatment. The following additional criteria shall be applied depending on age and the presence of comorbidities. - Aged younger than 65: Systolic blood pressure of 130 mmHg or higher or diastolic blood pressure of 80 mmHg or higher shall be applied to those with cardiovascular disease or an ACR or AER of 30 mg/g or higher. - Aged 65 or older: Regardless of comorbidities, systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90 mmHg or higher shall be applied. - Patients who agreed in writing to the Personal Information Collection and Usage Agreement after listening to the explanation of the objective, method, etc. of this observational study Exclusion Criteria: - Patients who are suspected of or confirmed with secondary hypertension - Those diagnosed with type 1 diabetes or secondary diabetes - Patients undergoing kidney dialysis or patients who received kidney transplants or those for whom kidney dialysis or kidney transplants are planned - If angiotensin converting enzyme inhibitors (ACEI) or renin inhibitors are used in conjunction or are planned to be used in conjunction - Patients with moderate to severe hepatic dysfunction (ALT and/or AST of over three times the upper limit of normal) or patients with biliary tract obstruction - Pregnant and breast-feeding women - Those who were administered with drugs for clinical studies within 12 weeks from the enrollment or those who plan on participating in other clinical studies while participating in this study - Other subjects who are considered inappropriate to participate in the study by the investigator's decision |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Severance hospital, Yonsei University Health System | Seoul |
Lead Sponsor | Collaborator |
---|---|
Boryung Pharmaceutical Co., Ltd |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of change in albuminuria (urine ACR) | The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the rate of change in albuminuria (urine ACR) at the baseline, on Week 8, and on Week 8 compared to the baseline shall be obtained | Week 8 | |
Secondary | Quantity of change in albuminuria (urine ACR) | The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the quantity of change in albuminuria (urine ACR) at the baseline, on Week 8, and on Week 8 compared to the baseline shall be obtained | Week 8 | |
Secondary | Rate of change in albuminuria (urine ACR) | The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the rate of change in albuminuria (urine ACR) at each time point, on Week 26 and Week 52 compared to the baseline shall be obtained | Week 26, Week 52 | |
Secondary | Rate of change in proteinuria (urine PCR) | The descriptive statistics (number of subjects, average, standard deviation, median, minimum value, quartile, and maximum value) regarding the rate of change in proteinuria (urine PCR) at each time point, on Week 8, Week 26, and Week 52 compared to the baseline shall be obtained | Week 8, Week 26, Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Terminated |
NCT04051957 -
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
|
Phase 2 | |
Terminated |
NCT02057523 -
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT02232763 -
Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria
|
Phase 3 | |
Completed |
NCT02226055 -
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
|
N/A | |
Completed |
NCT00493727 -
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
|
N/A | |
Active, not recruiting |
NCT00565396 -
Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Withdrawn |
NCT02882373 -
Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury
|
Phase 2 | |
Completed |
NCT02327403 -
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT01773382 -
The Effects of Weight Reduction in IgA Nephropathy
|
N/A | |
Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
Withdrawn |
NCT00541619 -
Sympathetic Overactivity in Essential Hypertension
|
N/A | |
Withdrawn |
NCT00392132 -
Impact of Screening Patients With HIV for Kidney Disease
|
||
Terminated |
NCT00001978 -
Determination of Kidney Function
|
||
Recruiting |
NCT05457283 -
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
|
Phase 3 | |
Completed |
NCT04874753 -
The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT02972346 -
Availability Study of ACTH to Treat Children SRNS/SDNS
|
N/A | |
Unknown status |
NCT02256995 -
uChek Pilot Study for Urinalysis in the Antenatal Care Setting
|
N/A |